Optimization of biologic therapy in Crohn’s disease

References

• Rogler G, Vavricka S, Schoepfer A, et al. Mucosal healing and deep remission: what does it mean? World J Gastroenterol. 2013;19(43):7552–7560.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Fiorino G, Buisson A, et al. First-line therapy in adult Crohn’s disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. 2013;10(6):345–351.
   PubMed Web of Science ®Google Scholar
• O’Toole A, Moss AC. Optimizing biologic agents in ulcerative colitis and Crohn’s disease. Curr Gastroenterol Rep. 2015;17(8):32,015–0453-1.
   PubMedGoogle Scholar
• Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7(3):213–221.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel J-F, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105(7):1574–1582.
   PubMed Web of Science ®Google Scholar
• Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644–659; quiz 660.
   PubMed Web of Science ®Google Scholar
• Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am J Gastroenterol. 2008;103(4):944–948.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–623.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2(7):542–553.
   PubMed Web of Science ®Google Scholar
• O’Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(1):1–6.
   PubMed Web of Science ®Google Scholar
• Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–1139.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumor necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–781.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22(8):1999–2015.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Sandborn WJ, Kim RB, et al. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109(7):994–1004.
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med. 2013;15(83):201–211.
   PubMed Web of Science ®Google Scholar
• Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford). 2007;46(12):1828–1834.
   PubMed Web of Science ®Google Scholar
• Wang S-L, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012;382(1–2):177–188.
   PubMed Web of Science ®Google Scholar
• Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF alpha antagonists. J Immunol Methods. 2011;373(1–2):229–239.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109(7):1055–1064.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen O, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2013;63:919–927.
   PubMed Web of Science ®Google Scholar
• De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2013;19(2):429–444.
   PubMed Web of Science ®Google Scholar
• Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14(4):550,557.e2.
   Web of Science ®Google Scholar
• Colombel JF, Panaccione R, Bossuyt P, et al. Superior endoscopic and deep remission outcomes in adults with moderate to severe Crohn’s disease managed with treat to target approach versus clinical symptoms: data from calm. Gastroenterology. 2017;152(5):S155.
   Web of Science ®Google Scholar
• Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1):80,84.e2.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;363:1086–1088.
   Google Scholar
• Colombel JF, Reinisch W, Mantzaris G, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41:734–746.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Jharap B, Sandborn WJ, et al. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn’s disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2016;45:50–62.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Adedokun OJ, Gasink C, et al. Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn’s disease: a SONIC post hoc analysis. Gastroenterology. 2017;152(5):S37–S38.
   Web of Science ®Google Scholar
• Bortlik M, Duricova D, Machkova N, et al. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scand J Gastroenterol. 2015;51(2):196–202.
   PubMed Web of Science ®Google Scholar
• Torres J, Boyapati R, Kennedy N, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149:1716–1730.
   PubMed Web of Science ®Google Scholar
• Louis E, Mary J, Vernier–Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.e5.
   PubMed Web of Science ®Google Scholar
• Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40:338–353.
   PubMed Web of Science ®Google Scholar
• Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:514–521.e4.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–1329.e3.
   PubMed Web of Science ®Google Scholar
• Van Stappen T, Vande Casteele N, Van Assche G, et al. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2017. DOI:10.1136/gutjnl-2016-313071.
   PubMedGoogle Scholar
• D’Haens G, Vermeire S, Lambrecht G, et al. Drug-level based dosing versus symptom-based dose adaptation in patients with Crohn’s disease: a prospective, randomized multicenter study (TAILORIX). Gastroenterology. 2016;150:S143.
   Web of Science ®Google Scholar
• Rubin D, Panaccione R, Chao J, et al. A practical, evidence-based guide to the use of adalimumab in Crohn’s disease. Curr Med Res Opin. 2011;27:1803–1813.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011;17:141–151.
   PubMed Web of Science ®Google Scholar
• Zittan E, Kabakchiev B, Milgrom R, et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn’s disease. J Crohns Colitis. 2016;10:510–515.
   PubMedGoogle Scholar
• Paul S, Moreau A, Del Tedesco E, et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1288–1295.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827–834.
   PubMed Web of Science ®Google Scholar
• Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. Ther Adv Gastroenterol. 2011;4(6):375–389.
   PubMedGoogle Scholar
• Colombel J-F, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:423–431.e1.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Wolf DC, Kosutic G, et al. Effects of transient and persistent anti-drug antibodies to certolizumab pegol. Inflamm Bowel Dis. 2017;23:1047–1056.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Mould D, Kosutic G, et al. Refinement of population pharmacokinetic model of certolizumab pegol in Crohnʼs disease patients to account for time varying nature of covariates. Inflamm Bowel Dis. 2016;22:S42.
   PubMed Web of Science ®Google Scholar
• Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin Gastroenterol Hepatol. 2017. DOI:10.1016/j.cgh.2016.11.023.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Battat R, Kopylov U, Bessissow T, et al. Association among ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017. DOI:10.1016/j.cgh.2017.03.032.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen O, et al. Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn’s disease patients failing infliximab. Dig Dis Sci. 2015;60:2762–2770.
   PubMed Web of Science ®Google Scholar
• Freeman K, Connock M, Auguste P, et al. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling. Health Technol Assess. 2016;20:1–288.
   Web of Science ®Google Scholar
• Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis. 2016.
   Google Scholar
• Ungar B, Haj-Natour O, Kopylov U, et al. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. Medicine. 2015;94(18):e673.
   PubMed Web of Science ®Google Scholar
• Subramaniam K, D’Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol. 2012;28:24–30.
   Web of Science ®Google Scholar
• Papamichael K, Mantzaris G, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease. Expert Opin Drug Saf. 2016;15:493–501.
   PubMed Web of Science ®Google Scholar
• Brandse JF, Vos LM, Jansen J, et al. Serum concentration of anti-TNF antibodies, adverse effects and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment. J Crohns Colitis. 2015;9(11):973–981.
   PubMed Web of Science ®Google Scholar
• Denadai R, Teixeira F, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517–524.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65:249–255.
   PubMed Web of Science ®Google Scholar